Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review.

Frontiers in oncology·2026
Same author

Closing Editorial-Special Issue on "Vaccines and Vaccination: HIV, Hepatitis Viruses and HPV".

Vaccines·2026
Same author

Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up study.

Frontiers in immunology·2026
Same author

Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.

European thyroid journal·2026
Same author

Editorial: HIV and the gut: novel insights into HIV pathogenesis, clinical implications and therapeutic approaches.

Frontiers in immunology·2026
Same author

Oral Treatment with EGCG, Folic Acid, Vitamin B12, and Hyaluronic Acid Improves HPV Clearance and Counteracts Its Persistence: A Clinical Study.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Clinical prognosis in BRAF-mutated PTC.

Efisio Puxeddu1, Sonia Moretti

  • 1Department of Internal Medicine, Center for Thyroid Proteomic and Genomic Research, University of Perugia, and Regional Oncology Referral Center, Santa Maria della Misericordia Hospital, Italy. efisio@dimisem.med.unipg.it

Arquivos Brasileiros De Endocrinologia E Metabologia
|September 25, 2007
PubMed
Summary

The BRAF mutation in papillary thyroid carcinoma (PTC) may indicate aggressive tumors, affecting genomic stability, invasiveness, and gene expression. Further research is needed to confirm its role as a reliable prognostic marker in clinical practice.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Experiment Videos

Last Updated: Jul 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • BRAF mutations are increasingly recognized as potential prognostic markers in papillary thyroid carcinoma (PTC).
  • Studies suggest BRAF mutations may drive aggressive tumor behavior and influence tumor development.

Purpose of the Study:

  • To review and summarize current evidence on the role of BRAF mutation as a prognostic marker in PTC.
  • To highlight conflicting findings and identify knowledge gaps for clinical application.

Main Methods:

  • Analysis of phenotypes in thyroid cell lines and transgenic mice with BRAF mutations.
  • Differential gene expression analysis comparing BRAF-mutated PTCs with other genetic alterations.
  • Review of existing literature correlating BRAF mutation with PTC clinico-pathological features.

Main Results:

  • BRAF mutation, unlike RET/PTC, induces genomic instability, higher invasiveness, tumor dedifferentiation, and apoptosis suppression.
  • Impaired expression of iodine metabolism genes, increased Glut-1 mRNA, silenced tumor suppressor genes, and elevated VEGF observed in BRAF-mutated PTC.
  • Controversial associations between BRAF mutation and unfavorable clinico-pathological features reported in literature.

Conclusions:

  • BRAF mutation influences key molecular pathways implicated in PTC aggressiveness.
  • Evidence for BRAF mutation as a consistent prognostic marker remains debated.
  • More data is required to establish BRAF mutation's routine clinical utility in PTC management.